EPS Bio Technology (4183) reported revenue of NT$12.6 million for Oct 2026, -72.1% year on year and -63.3% from the previous month. Revenue for Jan–Oct 2026 was NT$273.7 million (-35.7% year on year).
In Oct 2026, it ranked No. 130 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$12.6 million | -72.1% | -63.3% |
| Sep 2026 | NT$34.2 million | -31.0% | +8.0% |
| Aug 2026 | NT$31.7 million | -19.1% | +20.8% |
| Jul 2026 | NT$26.2 million | -37.2% | -28.8% |
| Jun 2026 | NT$36.8 million | +6.4% | -8.9% |
| May 2026 | NT$40.4 million | -30.9% | +42.9% |
| Apr 2026 | NT$28.3 million | -22.6% | +50.0% |
| Mar 2026 | NT$18.9 million | -64.8% | +11.0% |
| Feb 2026 | NT$17 million | -42.8% | -38.2% |
| Jan 2026 | NT$27.5 million | -25.3% | -37.6% |
| Dec 2025 | NT$44.1 million | -16.9% | +46.5% |
| Nov 2025 | NT$30.1 million | -38.8% | -33.1% |
| Oct 2025 | NT$45 million | +212.2% | -9.3% |
| Sep 2025 | NT$49.6 million | -10.8% | +26.7% |
| Aug 2025 | NT$39.2 million | +174.3% | -6.2% |
| Jul 2025 | NT$41.8 million | +26.9% | +20.6% |
| Jun 2025 | NT$34.6 million | -33.7% | -40.9% |
| May 2025 | NT$58.6 million | +4.4% | +60.3% |
| Apr 2025 | NT$36.5 million | +44.4% | -31.9% |
| Mar 2025 | NT$53.7 million | -1.9% | +80.5% |
| Feb 2025 | NT$29.7 million | +25.0% | -19.3% |
| Jan 2025 | NT$36.8 million | +89.1% | -30.7% |
| Dec 2024 | NT$53.1 million | +83.6% | +8.0% |
| Nov 2024 | NT$49.2 million | -18.5% | +241.3% |
| Oct 2024 | NT$14.4 million | -76.5% | -74.1% |
Jan–Oct 2026 cumulative: NT$273.7 million (-35.7% YoY)
Other Biotech & Medical companies
Compare with peers: EPS Bio Technology vs PEC / EPS Bio Technology vs Lotus Pharm / EPS Bio Technology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
訂單量減少
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16